Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 32 of the 47 sources its claims cite were checked for support.

Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review

Open access

Abstract

Background: Alzheimer’s disease (AD) is a debilitating neurodegenerative condition with few treatment options available. Drug repurposing studies have sought to identify existing drugs that could be repositioned to treat AD; however, the effectiveness of drug repurposing for AD remains unclear. This review systematically analyzes the progress made in drug repurposing for AD throughout the last decade, summarizing the suggested drug candidates and analyzing changes in the repurposing strategies used over time. We also examine the different types of data that have been leveraged to validate suggested drug repurposing candidates for AD, which to our knowledge has not been previous investigated, although this information may be especially useful in appraising the potential of suggested drug repurposing candidates. We ultimately hope to gain insight into the suggested drugs representing the most promising repurposing candidates for AD. Methods: We queried the PubMed database for AD drug repurposing studies published between 2012 and 2022. 124 articles were reviewed. We used RxNorm to standardize drug names across the reviewed studies, map drugs to their constituent ingredients, and identify prescribable drugs. We used the Anatomical Therapeutic Chemical (ATC) Classification System to group drugs. Results: 573 unique drugs were proposed for repurposing in AD over the last 10 years. These suggested repurposing candidates included drugs acting on the nervous system (17%), antineoplastic and immunomodulating agents (16%), and drugs acting on the cardiovascular system (12%). Clozapine, a second-generation antipsychotic medication, was the most frequently suggested repurposing candidate (N = 6). 61% (76/124) of the reviewed studies performed a validation, yet only 4% (5/124) used real-world data for validation. Conclusion: A large number of potential drug repurposing candidates for AD has accumulated over the last decade. However, among these drugs, no single drug has emerged as the top candidate, making it difficult to establish research priorities. Validation of drug repurposing hypotheses is inconsistently performed, and real-world data has been critically underutilized for validation. Given the urgent need for new AD therapies, the utility of real-world data in accelerating identification of high-priority candidates for AD repurposing warrants further investigation.

Overview

CoChat Summary

TL;DR

This 10-year literature review of 124 PubMed-indexed Alzheimer’s disease (AD) drug repurposing studies found 573 unique drugs proposed, but no single top candidate emerged and validation was inconsistent. Real-world data was rarely used for validation (5/124, 4%), despite being highlighted as a promising way to prioritize candidates.

Key findings

  • Across 124 studies published 2012–2022, 573 unique drugs were suggested for AD repurposing; 65% (370/573) were supported by only one study. Clozapine was the most frequently suggested candidate (N = 6), followed by nine drugs with N = 5: aripiprazole, risperidone, sunitinib, vandetanib, vorinostat, pioglitazone, tamoxifen, verapamil, and adenosine.
  • Suggested candidates commonly acted on the nervous system (17%), were antineoplastic/immunomodulating agents (16%), or acted on the cardiovascular system (12%). Within nervous system drugs, antipsychotics (19%), antidepressants (17%), and antiepileptics (15%) represented about half.
  • 61% (76/124) of studies performed validation, but only 4% (5/124) used real-world data. Among validated studies, 51% (39/76) had AD-specific validation; experimental studies validated more often (45/48, 94%) than computational studies (31/71, 44%).
  • Between 2012–2016, 184 unique prescribable drugs were proposed; between 2017–2022, 482 were suggested, with only 93 drugs overlapping between the two periods.

Methods

  • Queried PubMed with a full-text search for “Alzheimer’s” AND “drug repurposing,” limited to May 2012–May 2022; 353 results were manually screened, excluding 72 reviews and 157 out-of-scope articles, leaving 124 studies.
  • Extracted repurposing strategy (computational, experimental, or combination), suggested drug candidates, and validation plan; excluded the seven FDA-approved AD drugs from analysis.
  • Standardized drug names with RxNorm, mapped to prescribable ingredients, classified drugs using the Anatomical Therapeutic Chemical (ATC) system, and categorized validation as in vitro, in vivo, other, and AD-specific versus non-AD-specific.

Limitations

  • The authors state that focusing the literature search on PubMed may have missed AD drug repurposing candidates discussed in journals from other fields, such as computer science (e.g., IEEE journals indexed by Google).
  • The authors state that very few studies reported explicitly negative outcomes, suggesting potential selective reporting bias that may have affected results.
  • Evident from the text: the broad definition of AD included general repurposing tools and candidates for diseases including but not limited to AD, likely contributing to only about half of validations being AD-specific; the authors also note that lack of comprehensive experimental AD models limited their AD-specific validation analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2023.1257700

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Flow diagram for literature review.
FIGURE 1 Flow diagram for literature review.CC BY · PubMed Central
FIGURE 2 Breakdown of AD drug repurposing studies published between 2012 and 2022. The studies are colored by repurposing strategy (computational, experimental, or combination). Studies with validation are shown with hatching. The total number of studies published each year is shown in bold text, with the number of studies with validation provided in parentheses.
FIGURE 2 Breakdown of AD drug repurposing studies published between 2012 and 2022. The studies are colored by repurposing strategy (computational, experimental, or combination). Studies with validation are shown with hatching. The total number of studies published each year is shown in bold text, with the number of studies with validation provided in parentheses.CC BY · PubMed Central
FIGURE 3 Number of unique studies supporting each drug repurposing candidate.
FIGURE 3 Number of unique studies supporting each drug repurposing candidate.CC BY · PubMed Central
FIGURE 4 Original therapeutic indications of drugs suggested for repurposing in AD. Drug therapeutic indications are represented using their Level 1 ATC codes.
FIGURE 4 Original therapeutic indications of drugs suggested for repurposing in AD. Drug therapeutic indications are represented using their Level 1 ATC codes.CC BY · PubMed Central
FIGURE 5 Further breakdown of unique prescribable drug candidates suggested for AD repurposing. (A) Proposed drugs acting on the nervous system (ATC code N). (B) Antineoplastic and immunomodulating repurposing candidates (ATC code L). (C) Repurposing candidates acting on the cardiovascular system (ATC code C). Drugs in classes accounting for less than 5% of the total drug count have been classified as “Other unspecified”.
FIGURE 5 Further breakdown of unique prescribable drug candidates suggested for AD repurposing. (A) Proposed drugs acting on the nervous system (ATC code N). (B) Antineoplastic and immunomodulating repurposing candidates (ATC code L). (C) Repurposing candidates acting on the cardiovascular system (ATC code C). Drugs in classes accounting for less than 5% of the total drug count have been classified as “Other unspecified”.CC BY · PubMed Central
FIGURE 6 Changes in the AD drug repurposing landscape over time. The outermost ring of the sunburst plot represents drugs suggested by studies published between 2012 and 2016, with the size of each drug slice weighted by the number of unique supporting studies published during that time period. The innermost ring cumulatively adds drugs suggested by studies published in the last 5 years (between 2017 and 2022), providing a comprehensive breakdown of the AD repurposing candidates suggested between 2012–2022 and their literature support. Drug candidates are colored by their Level 1 ATC classification as shown in the center pie chart; for the purposes of this figure, drugs with more than one possible ATC code were mapped to a single code chosen at random. The drug slices corresponding to clozapine and demecarium are labeled. A high-resolution version of Figure 6 with all drug slices labeled is available as Supplementary Figure S1.
FIGURE 6 Changes in the AD drug repurposing landscape over time. The outermost ring of the sunburst plot represents drugs suggested by studies published between 2012 and 2016, with the size of each drug slice weighted by the number of unique supporting studies published during that time period. The innermost ring cumulatively adds drugs suggested by studies published in the last 5 years (between 2017 and 2022), providing a comprehensive breakdown of the AD repurposing candidates suggested between 2012–2022 and their literature support. Drug candidates are colored by their Level 1 ATC classification as shown in the center pie chart; for the purposes of this figure, drugs with more than one possible ATC code were mapped to a single code chosen at random. The drug slices corresponding to clozapine and demecarium are labeled. A high-resolution version of Figure 6 with all drug slices labeled is available as Supplementary Figure S1.CC BY · PubMed Central
FIGURE 7 (A) Sankey diagram showing the breakdown of the validations performed across the studies. Validation is classified as in vitro, in vivo, other, or none. In vivo validation is further subdivided into animal models, clinical trials, and patient data. Three studies used two different types of validation (counted separately in the figure). (B) Breakdown of repurposing strategy and validation for the six studies suggesting clozapine as a repurposing candidate for AD. Repurposing strategy is classified as experimental or computational. Validation is classified as in vitro, in vivo, or none.
FIGURE 7 (A) Sankey diagram showing the breakdown of the validations performed across the studies. Validation is classified as in vitro, in vivo, other, or none. In vivo validation is further subdivided into animal models, clinical trials, and patient data. Three studies used two different types of validation (counted separately in the figure). (B) Breakdown of repurposing strategy and validation for the six studies suggesting clozapine as a repurposing candidate for AD. Repurposing strategy is classified as experimental or computational. Validation is classified as in vitro, in vivo, or none.CC BY · PubMed Central
FIGURE 8 Breakdown of validation data types (AD-specific and nonspecific). 76 studies performed a validation; one study used two different types of AD-specific validation (N = 77 for entire pie chart).
FIGURE 8 Breakdown of validation data types (AD-specific and nonspecific). 76 studies performed a validation; one study used two different types of AD-specific validation (N = 77 for entire pie chart).CC BY · PubMed Central

Verification

Claims the paper makes

18 Valid · 2 Not valid · 8 Not checked · 94 Own results and interpretations

64 more claims · 5 with their cited sources checked

Create a free account to see all 122 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 39
  • Probably not a substantial claim. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Research works printed but not linked: 3

  1. 2022, Anatomical therapeutic chemical (ATC) classification
  2. 2022, Alzheimer’s association
  3. 2022, Prescribable RxNorm API - APIs

Cited by

See all 55

Metadata

Authors
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q.
Affiliations
  • Vanderbilt University Medical Center (US)
  • Emory University (US)
Corresponding author
Grabowska, Monika E.
Venue
Frontiers in Pharmacology
Published
2023-09-07
Volume
14
Pages
1257700-1257700
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4386502171
Cited by
55
References
53
Citations by year
2026: 8 · 2025: 25 · 2024: 21 · 2023: 1
FWCI
1.96
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Institute on Aging (R01AG065611, R01AG069900, F30AG080885)
  • National Institute of General Medical Sciences (T32GM007347, R01GM139891, T32GM152284)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, drug repurposing, clozapine, real-world data, antipsychotic drugs, anticancer agents, immunomodulating agents, cardiovascular drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review. https://app.cochat.ai/papers/10.3389/fphar.2023.1257700
The paper
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023). Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1257700

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.